Gal Robin L, Cohen Nathan J, Kruger Davida, Beck Roy W, Bergenstal Richard M, Calhoun Peter, Cushman Terra, Haban Amanda, Hood Korey, Johnson Mary L, McArthur Teresa, Olson Beth A, Weinstock Ruth S, Oser Sean M, Oser Tamara K, Bugielski Brian, Strayer Heidi, Aleppo Grazia
Jaeb Center for Health Research, Tampa, Florida.
Henry Ford Health System, Detroit, Michigan.
J Endocr Soc. 2020 Jun 23;4(9):bvaa076. doi: 10.1210/jendso/bvaa076. eCollection 2020 Sep 1.
The purpose of this study was to evaluate feasibility of initiating continuous glucose monitoring (CGM) through telehealth as a means of expanding access. Adults with type 1 diabetes (N = 27) or type 2 diabetes using insulin (N = 7) and interest in starting CGM selected a CGM system (Dexcom G6 or Abbott FreeStyle Libre), which they received by mail. CGM was initiated with a certified diabetes care and education specialist providing instruction via videoconference or phone. The primary outcome was days per week of CGM use during the last 4 weeks. Hemoglobin A (HbA) was measured at baseline and 12 weeks. Participant self-reported outcome measures were also evaluated. All 34 participants (mean age, 46 ± 18 years; 53% female, 85% white) were using CGM at 12 weeks, with 94% using CGM at least 6 days per week during weeks 9 to 12. Mean HbA decreased from 8.3 ± 1.6 at baseline to 7.2 ± 1.3 at 12 weeks ( < .001) and mean time in range (70-180 mg/dL, 3.9-10.0 mmol/L) increased from an estimated 48% ± 18% to 59% ± 20% ( < .001), an increase of approximately 2.7 hours/day. Substantial benefits of CGM to quality of life were observed, with reduced diabetes distress, increased satisfaction with glucose monitoring, and fewer perceived technology barriers to management. Remote CGM initiation was successful in achieving sustained use and improving glycemic control after 12 weeks as well as improving quality-of-life indicators. If widely implemented, this telehealth approach could substantially increase the adoption of CGM and potentially improve glycemic control for people with diabetes using insulin.
本研究的目的是评估通过远程医疗启动持续葡萄糖监测(CGM)作为扩大其可及性手段的可行性。患有1型糖尿病的成年人(N = 27)或使用胰岛素的2型糖尿病成年人(N = 7)且有启动CGM意愿者选择了一种CGM系统(德康G6或雅培瞬感),通过邮件接收该系统。由认证的糖尿病护理和教育专家通过视频会议或电话提供指导来启动CGM。主要结局是过去4周内每周使用CGM的天数。在基线和12周时测量糖化血红蛋白(HbA)。还评估了参与者自我报告的结局指标。所有34名参与者(平均年龄46±18岁;53%为女性,85%为白人)在12周时均在使用CGM,94%的参与者在第9至12周期间每周至少使用6天CGM。平均HbA从基线时的8.3±1.6降至12周时的7.2±1.3(P<0.001),平均血糖在目标范围内的时间(70 - 180 mg/dL,3.9 - 10.0 mmol/L)从估计的48%±18%增加到59%±20%(P<0.001),每天增加约2.7小时。观察到CGM对生活质量有显著益处,包括糖尿病困扰减轻、对血糖监测满意度增加以及管理中感知到的技术障碍减少。远程启动CGM成功实现了持续使用,并在12周后改善了血糖控制以及生活质量指标。如果广泛实施,这种远程医疗方法可能会大幅增加CGM的采用率,并有可能改善使用胰岛素的糖尿病患者的血糖控制。